Comparing Costs and Outcomes of Treatments for Irritable Bowel Syndrome With Diarrhea: Cost-Benefit Analysis

Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses

Gillian D Sanders, Peter J. Neumann, Anirban Basu et al. · JAMA · 2016 · 3K citations · Full text

Pharmacy, Health Administration, Health Policy +17

U. S. Householder survey of functional gastrointestinal disorders

Douglas A. Drossman, Zhiming Li, Eileen Andruzzi et al. · Digestive Diseases and Sciences · 1993 · 2.2K citations

Medicine, Internal Medicine, Gastroenterology +5

Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement

Don Husereau, Michael Drummond, Stavros Petrou et al. · BMJ · 2013 · 1.8K citations · Full text

Public Affairs, Health Policy, Pharmacoeconomics +16

Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation

Mark Pimentel, Anthony Lembo, William D. Chey et al. · New England Journal of Medicine · 2011 · 1K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40 000 subjects

A. P. S. Hungin, Peter J. Whorwell, Jan Tack et al. · Alimentary Pharmacology & Therapeutics · 2003 · 784 citations

Medicine, Clinical Sciences, Internal Medicine +16